Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination

Xueguang Lu,Shuai Liu,Lei Miao,Xinzhu Shan,Xingdi Cheng,Chen Yang,Yixing Wen,Yuanyuan Zhao,Jingjiao Li,Shiwei Mi,Haonan Huo,Wei Li,Jiaqi Lin,Xinghuan Ma

DOI: https://doi.org/10.26434/chemrxiv-2023-n079h

2023-11-23

Abstract:Inhaled delivery of messenger RNA (mRNA) using lipid nanoparticle (LNP) holds immense promise for treating pulmonary diseases or serving as a mucosal vaccine. However, the unsatisfactory delivery efficacy caused by the disintegration and aggregation of LNP during nebulization represents a major obstacle. To address this, we developed a charge-assisted stabilization (CAS) strategy aimed at inducing electrostatic repulsions among LNPs to enhance their colloidal stability. By optimizing the surface charges using a peptide-lipid conjugate, the leading CAS-LNP demonstrated exceptional stability during nebulization, resulting in efficient pulmonary mRNA delivery in mouse, dog, and pig. Inhaled CAS-LNP primarily transfect dendritic cells, triggering robust mucosal and systemic immune responses. We demonstrated the efficacy of inhaled CAS-LNP as a vaccine for SARS-CoV-2 Omicron variant and as a cancer vaccine to inhibit lung metastasis. Our findings illustrate the design principles of nebulized LNPs, paving the way of developing inhaled mRNA vaccines and therapeutics.

Chemistry

What problem does this paper attempt to address?

This paper aims to solve the problem of unsatisfactory delivery efficiency of lipid nanoparticles (LNP) caused by disintegration and aggregation during inhalation delivery. Specifically, the paper proposes a charge - assisted stabilization (CAS) strategy. By optimizing the surface charge of LNP and introducing electrostatic repulsion, the colloidal stability of LNP is enhanced. This method significantly improves the stability of LNP during the nebulization process, thereby achieving efficient pulmonary mRNA delivery. Studies have shown that inhaled CAS - LNP mainly transfects dendritic cells and triggers strong mucosal and systemic immune responses. In addition, the paper also verifies the effectiveness of inhaled CAS - LNP as a vaccine against the SARS - CoV - 2 Omicron variant and an anti - cancer vaccine to inhibit lung metastasis. This research result provides new design principles for the development of inhalable mRNA vaccines and therapeutic drugs.